NASDAQ: ALKSAlkermes PLC Stock
$27.00-0.20 (-0.74%)
Updated Apr 17, 2025
ALKS Price
$27.00
Fair Value Price
$45.22
Market Cap
$4.39B
52 Week Low
$22.90
52 Week High
$36.45
P/E
12.16x
P/B
3x
P/S
3.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.56B
Earnings
$367.07M
Gross Margin
84.2%
Operating Margin
29.61%
Profit Margin
23.6%
Debt to Equity
0.4
Operating Cash Flow
$439M
Beta
0.61
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ALKS Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALKS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ALKS
Ranked#9 of 54
Ranked#9 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important ALKS news, forecast changes, insider trades & much more!
ALKS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALKS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALKS ($27.00) is undervalued by 40.3% relative to our estimate of its Fair Value price of $45.22 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALKS ($27.00) is significantly undervalued by 40.3% relative to our estimate of its Fair Value price of $45.22 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ALKS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more ALKS due diligence checks available for Premium users.
Valuation
ALKS fair value
Fair Value of ALKS stock based on Discounted Cash Flow (DCF)
Price
$27.00
Fair Value
$45.22
Undervalued by
40.30%
ALKS ($27.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALKS ($27.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALKS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALKS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.16x
Industry
20.48x
Market
27.98x
ALKS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ALKS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ALKS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3x
Industry
1.99x
ALKS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALKS's financial health
Profit margin
Revenue
$430.0M
Net Income
$146.5M
Profit Margin
34.1%
ALKS's Earnings (EBIT) of $461.26M... subscribe to Premium to read more.
Interest Coverage Financials
ALKS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.1B
Liabilities
$590.6M
Debt to equity
0.4
ALKS's short-term assets ($1.42B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALKS's short-term assets ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALKS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALKS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$190.4M
Investing
-$13.9M
Financing
-$281.7M
ALKS's operating cash flow ($439.12M)... subscribe to Premium to read more.
Debt Coverage Financials
ALKS vs Pharmaceutical Stocks
Alkermes Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.